arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Stoke Therapeutics, Inc.

STOK

$32.72 ▲ +0.80 (+2.51%) at close

9 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Stoke Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B

Dividend Yield —

Revenue Growth 404.5% ↗

Op. Margin -11.2% ↗

ROIC -4.6% ↗

FCF / Share $0.76 ↗

Trailing P/E —

Price / Book 5.5x

FCF Yield 2.3%

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$184.42M

↑ +404.5% —

Net Income Profit after all expenses

$-6.88M

↑ +92.3% —

Operating Margin Operating profit as % of sales

-11.2%

↑ +96.0% 14th

FCF / Share Free cash flow per share

$0.76

↑ +147.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↑

Financial Health →

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue Growth YoY (%)	404.5% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+4956%)	316.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3854%)	-29.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-465%)	—	—	—	—	—	—
EPS Growth YoY (%)	92.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	30.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	8.5% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-11.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	92.3% Excellent ↑ Excellent Improving Year-over-year change in net income	15.0% Good ↑ Good Improving Year-over-year change in net income	-3.6% Weak ↑ Weak Improving Year-over-year change in net income	-17.8% Weak ↑ Weak Improving Year-over-year change in net income	-64.2% Weak ↑ Weak Improving Year-over-year change in net income	-61.6% Weak Weak Year-over-year change in net income	-158.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	N/M	14.2% Fair ↑ Fair Improving Year-over-year change in free cash flow	-104.0% Weak Weak Year-over-year change in free cash flow	50.3% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	145.9% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	-11.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-174%)	-277.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1949%)	—	—	—	—	—	—	—
Profit Margin (%) (%)	-3.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-131%)	-243.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2128%)	—	—	—	—	—	—	—
FCF Margin (%) (%)	24.4% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	-238.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-288.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	-6.52x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.35x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-4.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-35.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-56.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-9.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-4.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-50.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-40.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-17.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-11.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-2.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-113%)	-38.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-359%)	-65.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-537%)	-54.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-465%)	-39.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-363%)	-18.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-222%)	-14.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-196%)	-11.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-179%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Interest Coverage (x)	-2287.78x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-3898.92x Weak Weak Operating income divided by interest expense Optimal: > 5x	-2342.31x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—
Net Debt (USD)	$-84.22M	$-127.98M	$-191.44M	$-113.56M	$-144.90M	$-287.31M	$-222.47M	$-105.40M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$3.11	$0.68	$0.20	$0.32	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.12	$-1.65	$-2.38	$-2.60	$-2.34	—	—	—	—
Free Cash Flow per Share (USD)	$0.76	$-1.61	$-1.88	$-0.92	$-1.85	—	—	—	—
Book Value per Share (USD)	$5.98	$4.24	$3.47	$4.69	$5.90	$7.82	$6.83	$144.44	—
Tangible Book Value per Share (USD)	$5.98	$4.24	$3.47	$4.69	$5.90	$7.82	$6.83	$144.44	—
Basic Weighted Avg Shares (shares)	59.22M	54.01M	43.99M	38.90M	36.74M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$247.82M	$192.70M	$184.52M	$212.68M	$212.08M	$282.50M	$221.93M	$103.68M	—
Total Equity (USD)	$352.46M	$229.02M	$159.56M	$184.85M	$217.78M	$286.08M	$224.43M	$105.07M	$-1.29M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$184.42M	$36.55M	$8.78M	$12.40M	—	—	—	—	—
Depreciation Expense (USD)	$1.77M	$2.18M	$2.47M	$1.55M	$974.00K	$888.00K	$450.00K	$214.00K	—
Net Income, GAAP (USD)	$-6.88M	$-88.98M	$-104.70M	$-101.07M	$-85.81M	$-52.24M	$-32.33M	$-12.52M	—
Operating Cash Flow (USD)	$45.59M	$-86.85M	$-81.07M	$-31.87M	$-66.91M	$-42.22M	$-31.05M	$-10.96M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters

Stoke Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare STOK with peers